Collaborative R&D agreement for small molecule drugs against oncology-relevant protein-protein interactions (updated)

Boehringer Ingelheim
FORMA Therapeutics

Jan 05 2012
Collaborative R&D agreement for small molecule drugs against oncology-relevant protein-protein interactions (updated)

Companies:
- Boehringer Ingelheim
- FORMA Therapeutics

Announcement date: Jan 05 2012
Amendment date: Mar 10 2017
Deal value, US$m: 815.0 : sum of upfront and milestone payments

Details

- Financials

Financials

Deal value, US$m: 815.0 : sum of upfront and milestone payments
Upfront, US$m: 65.0 : upfront payment
Milestones, US$m: 750.0 : pre-commercial milestones for programs resulting from the collaboration
n/d : undisclosed payments for scientific advancements on January 2014
n/d : received clinical development milestone announced on March 2017

Press Release

March 2017

FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, announced the achievement of a clinical development milestone in their alliance with Boehringer Ingelheim (BI).

The partnership focuses on the discovery and development of novel drug candidates against protein-protein interactions for the treatment of cancer.

Financial milestones payable to FORMA for this achievement have not been disclosed.

17 June 2015

FORMA Therapeutics announced today the achievement of several discovery milestones in their alliance with Boehringer Ingelheim for the discovery of novel drug candidates against protein-protein interactions (PPI) for the treatment of cancer.
FORMA Therapeutics announced the achievement of several discovery milestones in their alliance with Boehringer Ingelheim for the discovery of novel drug candidates against protein-protein interactions for the treatment of cancer.

BI has formally internalized novel compounds for an oncology-relevant PPI program from FORMA.

FORMA will continue to conduct screening within the alliance, has expanded chemistry resourcing to prosecute validated scaffolds, and will continue to further interrogate additional targets named within the agreement.

FORMA will receive undisclosed payments as part of these recent scientific advancements.

05 January 2012 FORMA Therapeutics has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.

The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.

FORMA will receive a total of $65 million in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the next four years.

FORMA could be eligible for up to $750 million in pre-commercial milestones for programs resulting from the collaboration.

Further financial details were not disclosed.

Press Release

March 2017

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, today announced the achievement of a clinical development milestone in their alliance with Boehringer Ingelheim (BI). The partnership focuses on the discovery and development of novel drug candidates against protein-protein interactions for the treatment of cancer. Financial milestones payable to FORMA for this achievement have not been disclosed.

“FORMA’s discovery and early clinical development successes, across our wholly-owned pipeline as well as programs in collaboration with pharmaceutical partners, accentuates the value of a unique compound collection and productivity of talented teams across collaborative networks”

“FORMA’s discovery and early clinical development successes, across our wholly-owned pipeline as well as programs in collaboration with pharmaceutical partners, accentuates the value of a unique compound collection and productivity of talented teams across collaborative networks” said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. “We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs.”

About FORMA

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit.
Investment in creative and talented individuals, as well as fully exploiting various technology platforms, has provided FORMA with keen insights into three-dimensional protein structure and druggable binding pockets. We are quite pleased to have contributed to BI's drug discovery pipeline by identifying a panel of novel scaffolds across multiple targets."

"FORMA’s continued successes within the BI partnership, an agreement originally announced in January 2012 and with milestones achieved in 2014, underscore our ability to make tractable progress in the challenging area of protein-protein interactions," said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. "Our recent successes within the BI partnership, an agreement originally announced in January 2012, demonstrate FORMA’s ability to execute and deliver on challenging goals," said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. "Targeting PPIs is highly attractive for therapeutic intervention because they play a vital role in virtually all cellular processes. FORMA’s discovery engine has garnered critical insights into PPIs, which now instruct and guide our drug discovery initiatives." "Our recent successes within the BI partnership, an agreement originally announced in January 2012, demonstrate FORMA’s ability to execute and deliver on challenging goals," said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. "Targeting PPIs is highly attractive for therapeutic intervention because they play a vital role in virtually all cellular processes. FORMA’s discovery engine has garnered critical insights into PPIs, which now instruct and guide our drug discovery initiatives."

As part of the PPI alliance, BI has formally internalized novel compounds for an oncology-relevant PPI program from FORMA. Further, FORMA will continue to conduct screening within the alliance, has expanded chemistry resourcing to prosecute validated scaffolds, and will continue to further interrogate additional targets named within the agreement. FORMA will receive undisclosed payments as part of these recent scientific advancements.

Kenneth W. Bair, Ph.D., Chief Scientific Officer and Head of Research and Development, FORMA Therapeutics noted, "The combination of our cell-based screening technology (MAPPIT) and biochemical assay platforms provides a rapid way to screen for PPI inhibitors in two parallel formats, each offering distinct advantages. Further, integrating data from FORMA’s X-ray crystallography efforts across product pipeline targets with CS-Map technology interrogation of the surfaces for all human proteins in the Protein Data Bank (PDB) (~16,000) enabled the design and synthesis of shape-directed compound libraries biased toward shapes of druggable pockets on protein surfaces. The conformational flexibility of these novel molecules has proven essential to identify potential chemical starting material for PPIs of interest."

About FORMA

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.

09 January 2014

FORMA Therapeutics Announces Advancement of Collaboration with Boehringer Ingelheim for Modulating Protein-Protein Interactions in the Treatment of Cancer

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics announced today the achievement of several discovery milestones in their alliance with Boehringer Ingelheim (BI) for the discovery of novel drug candidates against protein-protein interactions (PPI) for the treatment of cancer.

"Targeting PPIs is highly attractive for therapeutic intervention because they play a vital role in virtually all cellular processes. FORMA’s discovery engine has garnered critical insights into PPIs, which now instruct and guide our drug discovery initiatives." "Our recent successes within the BI partnership, an agreement originally announced in January 2012, demonstrate FORMA’s ability to execute and deliver on challenging goals," said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. "Targeting PPIs is highly attractive for therapeutic intervention because they play a vital role in virtually all cellular processes. FORMA’s discovery engine has garnered critical insights into PPIs, which now instruct and guide our drug discovery initiatives."

As part of the PPI alliance, BI has formally internalized novel compounds for an oncology-relevant PPI program from FORMA. Further, FORMA will continue to conduct screening within the alliance, has expanded chemistry resourcing to prosecute validated scaffolds, and will continue to further interrogate additional targets named within the agreement. FORMA will receive undisclosed payments as part of these recent scientific advancements.

05 January 2012

FORMA Therapeutics, Inc. Cuts $815 Million Deal With Boehringer Ingelheim Corporation to Discover Cancer Drugs

WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics announced today that the Company has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer. The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.
Under the terms of the collaboration, FORMA will receive a total of $65 million in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the next four years. FORMA could be eligible for up to $750 million in pre-commercial milestones for programs resulting from the collaboration. Further financial details were not disclosed.

“Many of the ‘un-druggable’ and/or novel targets in oncology involve protein-protein interactions,” said Kenneth Bair, Ph.D., Senior Vice President and Head of Research and Development of FORMA. “We are really excited about tackling these essential targets with Boehringer Ingelheim.”

“This creative deal provides Boehringer Ingelheim with access to our drug discovery capabilities in cancer but also offers FORMA and our shareholders several opportunities to realize early return through assets developed under this collaboration,” commented Steven Tregay, Ph.D., Chief Executive Officer of FORMA.

About FORMA Therapeutics

FORMA Therapeutics targets essential cancer pathways to create transformative small molecule cancer therapies. FORMA’s novel approach to accessing high value drug targets, many of which pose significant challenges to conventional discovery approaches, leverages the integration of its innovative drug discovery technologies and oncology expertise, enabling efficient screening, discovery and rational development of small molecule drug candidates with qualified cellular mechanisms of action. FORMA is building a robust pipeline of cancer therapies in areas such as tumor metabolism, protein-protein interactions and epigenetics. FORMA is headquartered in Watertown, MA. www.formatherapeutics.com

Filing Data

Not available.

Contract

Not available.